HOME › DRUGS › UMECLIDINIUM BROMIDE
ACTIVE SUBSTANCE / INN

UMECLIDINIUM BROMIDE

Brand name(s): Incruse Ellipta (previously Incruse), INCRUSE ELLIPTA, TRELEGY ELLIPTA, ANORO ELLIPTA
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
NDA209482
Pulmonary Disease, Chronic Obstructive
ACTIVE SUBSTANCE
Umeclidinium Bromide
REGULATORS
FDA · EMA
SPONSORS / MAH
GlaxoSmithKline Trading Services Limited, GLAXO GRP ENGLAND, GLAXOSMITHKLINE
TOTAL APPLICATIONS
4
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
INCRUSE ELLIPTANDA205382GLAXO GRP ENGLANDPrescription
TRELEGY ELLIPTANDA209482GLAXOSMITHKLINEPrescription
ANORO ELLIPTANDA203975GLAXOSMITHKLINEPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
Incruse Ellipta (previously Incruse)GlaxoSmithKline Trading Services LimitedAuthorised28/04/2014Pulmonary Disease, Chronic Obstructive

FULL INTELLIGENCE ON UMECLIDINIUM BROMIDE

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →